| Literature DB >> 28200105 |
Claudia Hernandez-Armenta1, David Ochoa1, Emanuel Gonçalves1, Julio Saez-Rodriguez1,2, Pedro Beltrao1.
Abstract
MOTIVATION: Phosphoproteomic experiments are increasingly used to study the changes in signaling occurring across different conditions. It has been proposed that changes in phosphorylation of kinase target sites can be used to infer when a kinase activity is under regulation. However, these approaches have not yet been benchmarked due to a lack of appropriate benchmarking strategies.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28200105 PMCID: PMC5870625 DOI: 10.1093/bioinformatics/btx082
Source DB: PubMed Journal: Bioinformatics ISSN: 1367-4803 Impact factor: 6.937
Human kinases displaying specific regulation—up or down—in perturbations quantified using high-throughput phosphoproteomics
| Experimental condition | Kinases | Regulation | References |
|---|---|---|---|
| AKTi (Akt inhibitor VIII), AKTi (MK-2206),PI3Ki (GDC-0941), PI3Ki (PI-103),PIK3CA activation (H1047R) + inhibitor | AKT1 | down | |
| PIK3CA activation (E545K),PIK3CA activation (H1047R), RG7356 | AKT1 | up | |
| Anti-CD3, anti-CD3 + anti-CD28, Differentiation (PMA) | PRKCA | up | |
| PKCi (BIM-1),PKCi (Gö-6976) | PRKCA | down | |
| ATR inhibitor (VE-821) | ATR | down | |
| CAMK2i (KN-62),CAMK2i (KN-93) | CAMK2A | down | |
| Crizotinib | ALK | down | |
| Dasatinib (50 nM) | MAPK3,ABL,LCK | down | |
| DNA damage (Etoposide), DNA damage (Ionizing radiation), Early S (Thymidine), G1_S (Thymidine), Late S (Thymidine) | ATR, ATM | up | |
| EGF | AKT1, BRAF, EGFR, MAP2K1, MAP2K2, MAPK1, MAPK3, RAF1 | up | |
| EGFRi (PD-153035),EGFRi (PD-168393), Erlotinib,Gefitinib | EGFR | down | |
| EGF + SB202190 | MAPK14 | down | |
| EGF + U0126, MEKi (GSK-1120212),MEKi (U0126),Selumetinib (AZD6244) | MAP2K1, MAP2K2 | down | |
| ERKi (ERK inhibitor),ERKi (ERK inhibitor II),Dasatinib (50 nM) | MAPK1 | down | |
| Iloprost (5 nM) | PRKACA | up | |
| Mitosis (AZD1152), Mitosis (MLN8054) | AURKA | down | |
| Mitosis (AZD1152) | AURKB | down | |
| Mitosis (BI2536),Mitosis (short Taxol + BI2536),BI 4834 (on Mitosis Nocodazole), PLK1 Inhibitor (G2r - BI2536) | PLK1 | down | |
| mTORi (KU-0063794), mTORi (Torin-1),Rapamycin,Starved,Torin1 | MTOR | down | |
| PIK3CA activation (H1047R), PIK3CA activation (E545K) | PIK3CA | up | |
| P70S6K1i (DG2), P70S6K1i (PF-4708671) | RPS6KB1 | down | |
| ROCKi (H-1152), ROCKi (Y-27632) | ROCK1 | down | |
| Sorafinib | PDGFRB, PDGFRA, BRAF, RAF1, FLT1, FLT3, FLT4 | down | |
| Quizartinib | PDGFRA, FLT3 | down | |
| LRRK2-IN-1 (Endogenous LRRK2),LRRK2-IN-1 (LRRK2 overexpression) | LRKK2 | down | |
| VEGF | FLT4, FLT1 | up | |
| Vemurafenib (PLX4032) | BRAF | down |
Fig. 1Comparison of kinase activity prediction performances by methodology and number of known kinase substrates. The filtered gold standard of 149 kinase-condition pairs was assessed against the same number of 60 randomly generated negatives (dots)
Fig. 2Comparison of substrate-based kinase activity prediction methods weighting substrates by kinase binding specificity. Similar to Figure 1. ‘Weighted’ GSEA and Z-test include the similarity of the neighboring region to the kinase recognition motif to correct the relevance of each of the substrates (see ‘Methods’ section). Weighted and unweighted performances are based on the same set of kinases and conditions (135 positive kinase-condition pairs)
Fig. 3Benchmark of kinase activity predictions using in vivo, in vitro or in silico supported substrates. (A) AUC performance and (B) precision at recall 0.5. Positive kinase-condition pairs are 82, 48 and 75, respectively. The trend is maintained when down-sampling the number of substrate sites to guarantee a similar number of target sites for all cases (Supplementary Fig. S5) or restricting to the same set of kinases and conditions (Supplementary Fig. S6)